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Objective: Excisional surgery is the mainstay of treatment of Dupuytren’s disease.
Although outcomes are generally good, complications are common. The objective of
thisstudywastoevaluateintraoperativeandpostoperativecomplicationsassociatedwith
fasciectomy for Dupuytren’s disease. Methods: A literature search was conducted to
identifypublished,originalresearchthatreportedsurgicalcomplicationsassociatedwith
fasciectomy from 1988 to 2008. Search results were manually evaluated for relevance.
Complication rates according to types of disease (primary or recurrent disease) and
according to time (intraoperative vs postoperative) and type were collated. Results: A
total of 143 articles were identiﬁed; 41 met inclusion criteria, and of these, 28 reported
overall surgical complication rates ranging from 3.6% to 39.1%. Major complications
occurredin15.7%,includingdigitalnerveinjury3.4%,digitalarteryinjury2%,infection
2.4%,hematoma2.1%,andcomplexregionalpainsyndrome5.5%.Othercommon,more
minor injuries included ﬂare reaction in 9.9%, wound healing complications in 22.9%,
and a range of other complications. In the few (n = 3) studies in which primary and
recurrentdiseasesweredirectlycompared,digitalnerveinjuriesanddigitalarteryinjuries
were approximately 10 times more common in patients with recurrent disease (∼20%)
than those with primary disease (∼2%), though the numbers are too small for statistical
signiﬁcance.Conclusions:Areviewofpublishedreportsbysurgeonsshowsthatsurgical
fasciectomy for Dupuytren’s disease has a high number of complications. Surgeons
should be mindful of the potential for intraoperative and postoperative complications
and counsel their patients accordingly.
Dupuytren’s disease was originally noted by Plater in 16141 and carries the eponym
of Baron Guillaume Dupuytren, who ﬁrst lectured on the disease in 1831.2 Although Cline
in 1777 and Cooper in 1822 had described the fascial contracture and its treatment by
fasciotomy, they were not mentioned in Dupuytren’s discussions.1 Dupuytren’s disease
is a genetic disorder of abnormal collagen production and deposition in the hand that is
commonlycharacterizedbymetacarpophalangeal(MP)andproximalinterphalangeal(PIP)
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joint contractures in the ring and little ﬁngers. Dupuytren’s disease can affect all races, but
people of northern European descent are most commonly affected,3-5 with 3% to 6% of
white adults acquiring the condition during their lifetime.3,6 Dupuytren’s diathesis, which
manifestsasamoreaggressiveformofthedisease,comprisesapositivefamilyhistorywith
1 or more affected siblings or parents, male gender, age less than 50 years at onset, bilateral
involvement, ectopic manifestations (particularly Garrod’s pads), and Caucasian ethnicity.7
Furthermore, evidence indicates that Dupuytren’s disease is more likely to occur in those
with certain underlying conditions such as diabetes,8 thyroid disorders,9 alcoholism,10
and epilepsy.3 Lower incidences of Dupuytren’s occur in those afﬂicted by rheumatoid
arthritis.11
Genetic analyses show that Dupuytren’s disease is an autosomal dominant disor-
der with variable penetrance and gene expression.12 Genetic predisposition, combined
with diatheses, lifestyle choices, (eg, alcohol consumption), or trauma,13,14 can trig-
ger micro ruptures of the collagen ﬁbers of the palmar fascia, ﬁbroblast prolifera-
tion, and differentiation of ﬁbroblasts into myoﬁbroblasts.15,16 The expanding ﬁbroblast
pool and excess collagen deposition cause nodule and cord formation in the palm or
digits.
Dupuytren’s disease is progressive, with onset typically occurring later in life and
worsening over the course of several months to several years.17 In early stages, skin pitting
and dimpling are commonly observed as pretendinous bands connected to the dermis begin
to contract.18 Initially, nodules are painless and hand function is generally retained. How-
ever, as the disease progresses, cords begin to contract, causing ﬁnger ﬂexion deformities
and diminished hand function.18 The contractile properties of myoﬁbroblasts are thought
to cause the cords to shorten,15 resulting in the hallmark contractures that characterize
Dupuytren’s disease.
Few treatment options exist for those with Dupuytren’s contracture. Surgery is cur-
rentlythemainstayoftreatmentandisrecommendedforfunctionallyimpairedpatientswith
MP joint contractures of more than 30o.18-223 Indications for the treatment of PIP joint con-
tracture varies. Some authors recommend surgery for any degree of PIP contracture.20,22
Others feel that there should be approximately 15o (references 18, 24) or 30o (refer-
ence 25) of PIP contracture to warrant surgery. In contrast to these established guide-
lines, McGrouther asserts that it is better to “rely on functional difﬁculty and the rate
of progression when deciding on surgery, rather than choosing a set amount of joint
contracture.”26(p167)
Open, limited (subtotal) fasciectomy is the most commonly used surgical
procedure,10,27-30 but open or closed fasciotomies, including percutaneous needle fas-
ciotomy (ie, needle aponeurotomy), are also performed.31−35 Although surgery provides
positive outcomes for most patients, extensive hand therapy is typically required after
surgery. Not all patients with Dupuytren’s contracture are candidates for surgery; advanced
age, comorbidities, or both, often exclude patients from undergoing fasciectomy. In this
circumstance, closed fasciotomy26,36 or needle aponeurtomy35 is often recommended. To
date, no effective pharmacotherapy has been approved for the treatment of Dupuytren’s
disease,37 though an investigational procedure with Clostridium histolyticum collagenase
(enzymatic fasciotomy) shows promise.38
Dupuytren’s disease is not curable because it is a genetic disease and has
a cellular basis. Surgeons can help improve hand impairment due to Dupuytren’s
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disease by surgical techniques. These corrective surgical procedures improve hand
function for most patients; however, intraoperative and postoperative complications
are common. Recurrent disease is possible after all types of treatments, including
fasciectomies.
Surgeons performing fasciectomies need to discuss potential complications and recur-
rencewiththeirpatientsandsetrealisticexpectationsforefﬁcacyandsafety.Unfortunately,
noconcisesourceofestimatedsurgicalcomplicationratesexists.Thepurposeofthisreview
is to provide a single resource of intraoperative and postoperative complications associated
with fasciectomy for Dupuytren’s disease.
METHODS
Identiﬁcation of studies
Analysis of surgical complications was limited to those associated with fasciectomy
and aponeuroectomy. To identify published, original research that reported surgical
complications associated with surgery for Dupuytren’s disease, a MEDLINE search
was conducted with the following search parameters: fasciectomy[Title/Abstract] OR
aponeurectomy[Title/Abstract] OR surgery[Title/Abstract] OR operate*[Title/Abstract]
AND Dupuytren*[Title/Abstract] NOT review[Publication Type]. Search limitations in-
cluded human subjects, English language, and dates of October 31, 1988, to October 31,
2008.
Study selection
Search results were manually evaluated for relevance. Studies that did not report complica-
tion rates associated with fasciectomy or aponeurectomy were not included in the analysis.
Studies that reported complication rates associated with fasciotomy, aponeurotomy, ampu-
tation, or postsurgical application of the S-Quattro external ﬁxation device were excluded.
Case studies were also excluded.
Data analysis
Overall complication rates, complication rates according to types of disease (primary
or recurrent disease), and complication rates according to time (intraoperative vs post-
operative) and type were collated. Studies that did not speciﬁcally state whether pa-
tients had primary disease or recurrent disease were assumed to have had primary
disease.
Averages and ranges were calculated for each complication described. The manner in
which complications were reported varied from study to study (ie, by ray/ﬁnger; by hand;
by patient); conversion of all surgical complication rates to a common denominator was
not possible. Average rates were calculated and ranges were reported for each surgical
complication across studies; the sum of all numerators was divided by the sum of all
denominators and multiplied by 100.
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RESULTS
Study attributes
A total of 143 articles were identiﬁed. One hundred two articles were excluded from
the analysis (pathology, n = 16; treatment techniques, n = 17; postoperative care, n =9 ;
case studies, n = 13; long-term follow-up, n = 8; risk factors, n = 10; non-Dupuytren’s
disease, n = 12; surgery other than fasciectomy, n = 3; and other, n = 14). The remaining
41 articles met the inclusion criteria, reported complications associated with surgery for
Dupuytren’s disease, and were deemed appropriate for analysis: 27 evaluated primary (or
otherwise not speciﬁed) disease, 2 evaluated recurrent disease, and 12 evaluated mixed
populations (primary or recurrent disease) (Table 1).4,10,27,30,32,39-74 Of the 41 studies, 28
studies reported overall surgical complication rates ranging from 3.6% to 39.1%.
Complications in patients with primary disease
Of the 27 studies that evaluated patients with primary disease,10,32,47-63,65-71,74 16 stud-
ies reported intraoperative complications. These complications included digital nerve
injury (3.4%; range, 0.0%–7.7%) and digital artery injury (2.0%; range, 0.0%–2.6%)
(Table 2).*
All 27 primary-disease studies reported postoperative complications,10,32,47-63,65-71,74
the most common being wound-healing complications (22.9%; range, 0.0%–86.0%), in-
cisional scar pain (17.4%), dysesthesia/paresthesia (13.5%), hypoesthesia (10.1%; range,
6.0%–17.9%), ﬂare reaction (9.9%; range, 2.1%–51.5%), reﬂex sympathetic dystrophy
(5.8%; range, 0%–69.2%), infection (2.4%; range, 0–8.6%), and hematoma (2.1%; range,
0%–13%).
Complications in patients with recurrent disease
Only2studiesexaminedpatientswithrecurrentdiseaseexclusively.Onestudydidnotreport
intraoperativecomplications;the other evaluatedintraoperativecomplicationsand reported
no digital artery injuries (Table 3).72,73 Both studies reported postoperative complications:
hyperesthesia (20.0%), local cold intolerance (20.0%), hypoesthesia (15.8%), and necrosis
(11.1%).Nocasesofbleeding,infection,graftfailure,orreﬂexsympatheticdystrophywere
observed.
Complications in mixed populations (primary and recurrent diseases combined)
Seven studies reported intraoperative complications in a mixed population (ie, primary and
recurrent disease populations combined). The overall intraoperative complications in these
studies were digital nerve injury (3.6%; range, 0.6%–7.8%), digital artery injury (3.3%;
range, 0.8–9.7%), and tendon injury (0.02%) (Table 4).4,27,30,40,44,46,64
Eleven mixed-population studies reported overall postoperative complications: the
most common were stiffness (15.4%; range, 1.6%–51.5%), hypoesthesia (14.0%), scar
hypertrophy (10.0%), and scar contracture (9.4%).4,27,30,39-43,45,46,64
∗References 10, 32, 47, 49, 51-55, 57, 58, 61, 62, 65, 68, 71.
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Table 2. Reported complications∗ of surgery for primary Dupuytren’s disease
No. of studies
reporting
Complication complications Average, % (n/N)R a n g e , %
Intraoperative
Digital artery injury10,52,54,71 4 2.0 (20/989) 0–2.6
Digital nerve injury† 15 3.4 (51/1510) 0–7.7
Postoperative
Amputation (classiﬁed as postoperative
complication)10
1 1.5 (4/261) ...
Carpal tunnel syndrome56,62 2 6.4 (3/47) 3.6–10.5
Clinodactyly50 1 3.0 (1/33) ...
Complex regional pain syndrome (see
“reﬂex sympathetic dystrophy”)
... ...
Contracture48,63 2 6.7 (3/45) 6.2–7.7
Dysesthesia or paresthesia32,59 2 13.5 (15/111) 3.7–22.8
Edema62 1 7.1 (2/28) ...
Flare reaction66,71 2 9.9 (92/925) 2.1–51.5
Flexion, loss of47,49 2 4.2 (4/96) 4.0–4.3
Hematoma32,48-50,55,57,59,68,70 9 2.1 (14/657) 0–13.0
Hyperesthesia50 1 3.0 (1/33) ...
Hypoesthesia50,52,62 3 10.1 (10/99) 6.0–17.9
Incisional scar pain57 1 17.4 (4/23) ...
Infection‡ 19 2.4 (44/1860) 0–8.6
Necrosis (skin, ﬂap, or
graft)10,49,50,52,53,59,60,62,68,69
10 4.3 (31/713) 0–10
Pain (not otherwise speciﬁed)50,59 2 13.8 (12/87) 3–20.3
Reﬂex sympathetic dystrophy (complex
regional pain syndrome)10,49-53,57-63,65,70,71
16 5.8 (106/1828) 0–69.2
Stiffness62 1 3.6 (1/28) ...
Swan neck deformity54 1 7.1 (1/14) ...
Tenosynovitis50 1 3.0 (1/33) ...
“Trigger ﬁnger”56 1 5.3 (1/19) ...
Wound-healing complication32,47,49,58,60,62,66,67   8 22.9 (145/634) 0–86.0.
∗Studies that reported no cases of a particular complication were included in calculations.
†References 10, 32, 47, 49, 51, 53-55, 57, 61, 62, 65, 68, 71.
‡References 10, 32, 48-50, 52-56, 60, 62, 65, 67-71, 74.
§Includes cases of algodystrophy.
 One study reported no wound dehiscence.
Comparison of complications in patients with primary or recurrent disease
Three studies reported surgical complication rates separately for patients with primary
disease and recurrent disease (Table 5 and Fig 1).27,30,64 Only one study reported overall
complication rates, which were slightly higher in patients with primary disease (30.8%)
than in those with recurrent disease (25.0%).64 Digital artery injury and digital nerve injury
were more commonly observed in patients with recurrent disease than those with primary
disease.Theincidenceofdigitalarteryinjuryanddigitalnerveinjurywas1.7%(3/174)and
3.1% (7/224), respectively, in patients with primary disease and 25.7% (9/35) and 17.0%
(10/59), respectively, in patients with recurrent disease, indicating a approximately 10-fold
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difference (∼2% vs ∼20%) (Fig 1).27,30,64 However, the number of patients is too small for
statistical signiﬁcance.
Table 3. Reported complications∗ of surgery for recurrent Dupuytren’s disease
No. of studies
Complication reporting complication Average, % (n/ N)
Intraoperative
Digital artery injury73 (anesthetic) 1 0 (0/19)
Postoperative
Bleeding72 1 0 (0/17)
Graft failure73 1 0 (0/19)
Hyperesthesia72 1 20.0 (3/15)
Hypoesthesia73; poor to fair numbness noted postoperatively 1 15.8 (3/19)
Infection72,73 2 0 (0/36)
Necrosis (skin, ﬂap, or graft)72,73 2 11.1 (4/36)
Reﬂex sympathetic dystrophy (complex regional pain
syndrome)73
1 0 (0/19)
Local cold intolerance72 1 20.0 (3/15)
∗Studies that reported no cases of a particular complication were included in calculations.
Figure 1. Surgical complications in studies (n = 3)27,30,64 that compared primary disease versus
recurrent disease.
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Table 4. Reported complications∗ of surgery for primary and recurrent Dupuytren’s diseases
(mixed populations)
No. of studies
Complication reporting complication Average, % (n/N)R a n g e , %
Intraoperative
Digital artery injury27,30,46 3 3.3 (14/422) 0.8–9.7
Digital nerve injury4,27,30,40,44,46,64 7 3.6 (135/3779) 0.6–7.8
Tendon injury4 1 0.2 (5/2919) . ..
Postoperative
Bleeding4 1 1.2 (35/2919) . ..
Complex regional pain syndrome (see “reﬂex
sympathetic dystrophy”)
Carpal tunnel syndrome46 1 0.8 (2/253) . ..
Severe dysesthesia leading to amputation27 1 1.0 (1/103) . ..
Flexion, loss of30 1 1.5 (1/66) . ..
Graft failure leading to amputation42 1 3.1 (1/32) . ..
Hematoma27,30,40,46,64 5 1.8 (13/711) 1.3–2.9
Hypoesthesia43 1 14.0 (6/43) . ..
Infection4,27,30,46,64 5 3.9 (134/3424) 0.9–10.5
Necrosis (skin, ﬂap, or graft)4,30,40,45,46,64 6 2.5 (93/3780) 0–9.2
Transient paralysis27† 1 0.9 (1/103) . ..
Reﬂex sympathetic dystrophy (complex
regional pain syndrome)27,40,41,46,64
5 4.5 (34/752) 0–18.4
Scar contracture from graft42 1 9.4 (3/32) . ..
Scar hypertrophy39 1 10.0 (1/10) . ..
Stiffness27,45 2 15.4 (55/356) 1.6–51.5
Vascular damage45 1 0.8 (2/253) . ..
Wound dehiscence30 1 4.5 (3/66) . ..
Wound-healing complications such as skin
edge necrosis or slough46
1 1.2 (3/253) . ..
∗Studies that reported no cases of a particular complication were included in calculations.
†Transient paralysis assumed to be caused by a tourniquet.
Table 5. Intrastudy comparison of surgical complications∗ in patients with primary or recurrent
Dupuytren’s disease
Complication Primary, % (n/N) Recurrent, % (n/N)
Overall 30.8 (16/52)64 25.0 (6/24)64
Digital nerve injury 1.3 (1/77)27 26.9 (7/26)27
1.5 (1/95)30 22.2 (2/9)30
9.6 (5/52)64 4.2 (1/24)64
Digital artery injury 2.6 (2/77)27 30.8 (8/26)27
1.0 (1/97)30 11.1 (1/9)30
Hematoma 1.9 (1/52)64 0 (0/24)64
0 (0/77)27 7.7 (2/26)27
Skin necrosis (marginal) 7.7 (4/52)64 12.5 (3/24)64
Infection (superﬁcial) 12.0 (6/52)64 4.2 (1/24)64
Infection (deep joint infection that led to amputation) 0 (0/52)64 4.2 (1/24)64
∗Studies that reported no cases of a particular complication were included in calculations.
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DISCUSSION
Data from this analysis clearly demonstrate that complications associated with fasciectomy
for the treatment of patients with Dupuytren’s disease are varied and relatively common.
Data from studies that evaluated patients with primary disease showed that wound-healing
complicationsandpainweremostcommon.Conversely,patientswithrecurrentdiseasewere
more likely to experience varied types of sensory abnormalities (eg, hyperesthesia, cold
intolerance, hypoesthesia) and necrosis. Data from the few studies that directly compared
patients with primary and recurrent diseases showed that digital nerve injuries and digital
arteryinjuriesweremuchmorecommoninpatientswithrecurrentdisease(typically∼20%)
than those with primary disease (typically ∼2%), although larger numbers of patients are
needed for a valid statistical comparison. Pain was less common in patients with recurrent
disease, perhaps because those who previously underwent fasciectomy and developed a
pain-related complication were unlikely to undergo surgery a second time.
Surgical complication rates in the present analysis were physician reported. A large
patient survey study (N = 1177) conducted by the British Society for Surgery of the Hand
provides insight into patient-reported complications after Dupuytren’s surgery.75 Patients
with Dupuytren’s diseasewere identiﬁed by hand surgeons throughout the United Kingdom
and were invited to complete a questionnaire about surgical outcomes and complications.
Patients’ self-reported complications were 35.8% for numbness and 19.8% for infection.75
These values are much higher than the physician-reported complications rates provided in
the current analysis.75
As with all surgeries, complication rates generally correlate with invasiveness of the
procedure. Patients with severe disease often have greater tissue involvement and require
more complex measures to correct the ﬁnger deformity. Consequently, patients with severe
diseaseatthetimeofsurgerytendtoexperiencemorecomplicationspostfasciectomy.46,75 A
retrospectiveanalysisof 253 patientswith Dupuytren’s diseasewho underwent fasciectomy
showedthatcomplicationratesincreasedwiththeseverityofdisease,particularlywhenPIP
joint contracture was more than 60◦.46 Dias and Braybrooke75 made a similar observation,
showing a clear relationship between the incidence of self-reported complications and the
severity of the initial deformity, with patients who had severe disease at the time of surgery
reporting more surgical complications. Loos et al4 in a large study of almost 3000 patients
noted a statistically signiﬁcant correlation between worsening stage of the disease and
postoperative complications.
Several limitations of the present analysis must be taken into consideration when
interpreting the data. First, the manner in which complication rates were reported varied
from study to study and included complications per ray or ﬁnger, per patient, and per
hand. Conversion of complication rates to one common denominator was not possible,
so the overall rates and ranges represent blended data. Given the large number of studies
(n = 41) included in the analysis, overall interpretation should not be affected, though this
limitation may explain why the ranges associated with some complications are relatively
broad.Second,severalfactors,suchaspatientdiathesis,baselinediseaseseverity,thetypeof
jointaffected(ie,MPorPIP),andmultipledigitinvolvement,thatcanimpactthefrequency
of surgical complications were not analyzed separately. Complication rates in the present
analysis are therefore based on a heterogeneous patient population and cannot be directly
compared with a speciﬁc patient subset.
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In the absence of an approved pharmacotherapy, surgery provides the best opportunity
for long-term functional improvement for patients with Dupuytren’s disease. Although
complete restoration of hand function is unlikely, most patients will experience signiﬁcant
gain in function. However, several drawbacks to surgery exist. First, surgery does not cure
Dupuytren’s disease and recurrences rates are high, ranging from 26% to 80%.37 Second,
surgery in patients with recurrent disease is usually more challenging because scarring
and anatomic distortion from prior procedure(s) increases the likelihood of neurovascular
complications. Third, rehabilitation after open surgery may be prolonged. Finally, multiple,
repetitive surgical procedures have their limitations and not all patients are good candidates
for surgery.
CONCLUSIONS
This is the ﬁrst report to extensively collect and analyze complications associated with
surgery for Dupuytren’s disease in clinical practice. Data from this study indicate that
complications of surgery not only occur frequently but are also varied. Therefore, surgeons
who perform fasciectomies for Dupuytren’s disease should be mindful of the potential for
intraoperative and postoperative complications and should counsel their patients accord-
ingly. Furthermore, the severity of the disease and surgical history of the patient should be
considered when anticipating complications. Patients undergoing fasciectomy for recurrent
disease are more likely to experience either digital nerve injury or digital artery injury than
patients with primary disease.
In conclusion, results of this study underscore the importance of treating Dupuytren’s
asanincurablegeneticdiseaseunderstandingthatsurgicalexcision,fasciectomy,hasahigh
rate of major and minor complications. Surgeons must understand that while fasciectomy
for Dupuytren’s does offer a chance at long-term “straight” ﬁngers, there is a high cost in
terms of numbers of complications that are borne by the patient.
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